{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:49:40Z","timestamp":1789080580345,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006260","name":"Technion - Israel Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006260","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-transplant lymphoproliferative disorder (PTLD) is a devastating complication of immunosuppressive treatment in both solid organ transplantations (SOT) and hematopoietic stem cell transplantations (HSCT). Epstein-Barr virus (EBV) infection precedes PTLD in 90% of patients. Rituximab, a monoclonal anti-CD20 antibody, depletes B-lymphocytes, which are the ultimate reservoir for EBV. Although rituximab therapy is commonly used as a preventive measure for PTLD in high-risk HSCT, it is not established in SOT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pediatric kidney transplant recipients (PKTR) underwent routine EBV-PCR surveillance. Patients with increasing viral loads, despite immunosuppressive dose reduction, were managed with preventive rituximab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2012 and 2023, we identified eight episodes of asymptomatic EBV-PCR-positive blood tests in seven out of 65 PKTR (11%) under our care. EBV DNAemia emerged 120\u2013720\u00a0days post-transplantation. Five of seven patients with EBV DNAemia (71%) were EBV-seronegative prior to transplantation. All five patients did not respond to MMF dose reduction and were therefore treated with preventive rituximab therapy. Following this treatment, EBV PCR clearance was observed in all patients with only minimal complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PKTR who are EBV-na\u00efve prior to transplantation are expected to have a higher prevalence of EBV DNAemia. We found that PKTR who were EBV seronegative prior to transplantation were less likely to achieve EBV clearance in response to immunosuppression dose reduction. We suggest that rituximab therapy in PKTR may be safe and effective in EBV clearance and PTLD prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-024-06522-2","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:02:24Z","timestamp":1728291744000},"page":"829-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-3165","authenticated-orcid":false,"given":"Shirley","family":"Pollack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Plonsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Tibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Libinson-Zebegret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Yakobov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Eisenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Magen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"6522_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/children8080661","volume":"8","author":"A Baker","year":"2021","unstructured":"Baker A, Frauca Remacha E, Torres Canizales J et al (2021) Current practices on diagnosis, prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation: results of ERN TransplantChild Healthcare Working Group Survey. Children (Basel) 8:661. https:\/\/doi.org\/10.3390\/children8080661","journal-title":"Children (Basel)"},{"key":"6522_CR2","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00467-020-04790-2","volume":"36","author":"C Robinson","year":"2021","unstructured":"Robinson C, Chanchlani R, Kitchlu A (2021) Malignancies after pediatric solid organ transplantation. Pediatr Nephrol 36:2279\u20132291. https:\/\/doi.org\/10.1007\/s00467-020-04790-2","journal-title":"Pediatr Nephrol"},{"key":"6522_CR3","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/ndt\/gfx356","volume":"33","author":"A Francis","year":"2018","unstructured":"Francis A, Johnson DW, Teixeira-Pinto A, Craig JC, Wong G (2018) Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. Nephrol Dial Transplant 33:881\u2013889. https:\/\/doi.org\/10.1093\/ndt\/gfx356","journal-title":"Nephrol Dial Transplant"},{"key":"6522_CR4","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","volume":"27","author":"MS Sampaio","year":"2012","unstructured":"Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV (2012) Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant 27:2971\u20132979. https:\/\/doi.org\/10.1093\/ndt\/gfr769","journal-title":"Nephrol Dial Transplant"},{"key":"6522_CR5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","volume":"8","author":"RA McDonald","year":"2008","unstructured":"McDonald RA, Smith JM, Ho M et al (2008) Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 8:984\u2013989. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02167.x","journal-title":"Am J Transplant"},{"key":"6522_CR6","doi-asserted-by":"publisher","first-page":"1087864","DOI":"10.3389\/fped.2022.1087864","volume":"10","author":"R Fulchiero","year":"2022","unstructured":"Fulchiero R, Amaral S (2022) Post-transplant lymphoproliferative disease after pediatric kidney transplant. Front Pediatr 10:1087864. https:\/\/doi.org\/10.3389\/fped.2022.1087864","journal-title":"Front Pediatr"},{"key":"6522_CR7","unstructured":"The impact of induction therapy on the risk of posttransplant lymphoproliferative disorder in adult kidney transplant recipients with donor-recipient serological Epstein-Barr virus mismatch - ScienceDirect. Accessed July 28, 2024. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1600613524001709?via%3Dihub"},{"key":"6522_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s11899-023-00708-5","volume":"18","author":"M Ford","year":"2023","unstructured":"Ford M, Orlando E, Amengual JE (2023) EBV Reactivation and lymphomagenesis: more questions than answers. Curr Hematol Malig Rep 18:226\u2013233. https:\/\/doi.org\/10.1007\/s11899-023-00708-5","journal-title":"Curr Hematol Malig Rep"},{"key":"6522_CR9","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","volume":"2","author":"VR Dharnidharka","year":"2016","unstructured":"Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S (2016) Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers 2:15088. https:\/\/doi.org\/10.1038\/nrdp.2015.88","journal-title":"Nat Rev Dis Primers"},{"key":"6522_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00467-019-04284-w","volume":"35","author":"OM Martinez","year":"2020","unstructured":"Martinez OM (2020) Biomarkers for PTLD diagnosis and therapies. Pediatr Nephrol 35:1173\u20131181. https:\/\/doi.org\/10.1007\/s00467-019-04284-w","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 3","key":"6522_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1-155. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02834.x","journal-title":"Am J Transplant"},{"key":"6522_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14350","volume":"28","author":"M Green","year":"2024","unstructured":"Green M, Squires JE, Chinnock RE et al (2024) The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: II\u2014consensus guidelines for prevention. Pediatr Transplant 28:e14350. https:\/\/doi.org\/10.1111\/petr.14350","journal-title":"Pediatr Transplant"},{"key":"6522_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00467-007-0582-3","volume":"24","author":"VR Dharnidharka","year":"2009","unstructured":"Dharnidharka VR, Araya CE (2009) Post-transplant lymphoproliferative disease. Pediatr Nephrol 24:731\u2013736. https:\/\/doi.org\/10.1007\/s00467-007-0582-3","journal-title":"Pediatr Nephrol"},{"key":"6522_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.trre.2016.12.001","volume":"31","author":"J Le","year":"2017","unstructured":"Le J, Durand CM, Agha I, Brennan DC (2017) Epstein-Barr virus and renal transplantation. Transplant Rev 31:55\u201360. https:\/\/doi.org\/10.1016\/j.trre.2016.12.001","journal-title":"Transplant Rev"},{"key":"6522_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13147","volume":"22","author":"M Yamada","year":"2018","unstructured":"Yamada M, Nguyen C, Fadakar P et al (2018) Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients. Pediatr Transplant 22:e13147. https:\/\/doi.org\/10.1111\/petr.13147","journal-title":"Pediatr Transplant"},{"key":"6522_CR16","doi-asserted-by":"publisher","DOI":"10.2174\/1874303X014070100123","author":"A Moudgil","year":"2014","unstructured":"Moudgil A, Martz K, Moore T, Harmon WE, Dharnidharka VR (2014) Significance of asymptomatic persistent Epstein-Barr viral load in pediatric renal transplant recipients: North American pediatric renal trials and collaborative studies report. The Open Urology & Nephrology Journal. https:\/\/doi.org\/10.2174\/1874303X014070100123","journal-title":"The Open Urology & Nephrology Journal"},{"key":"6522_CR17","doi-asserted-by":"publisher","unstructured":"Styczynski J, van der Velden W, Fox CP et al (2016) Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 101:803\u2013811. https:\/\/doi.org\/10.3324\/haematol.2016.144428","DOI":"10.3324\/haematol.2016.144428"},{"key":"6522_CR18","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","volume":"28","author":"AM Evens","year":"2010","unstructured":"Evens AM, David KA, Helenowski I et al (2010) Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038\u20131046. https:\/\/doi.org\/10.1200\/JCO.2009.25.4961","journal-title":"J Clin Oncol"},{"key":"6522_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2024.151503","volume":"44","author":"VR Dharnidharka","year":"2024","unstructured":"Dharnidharka VR, Ruzinova MB, Marks LJ (2024) Post-transplant lymphoproliferative disorders. Semin Nephrol 44:151503. https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151503","journal-title":"Semin Nephrol"},{"key":"6522_CR20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/j.1600-6143.2011.03478.x","volume":"11","author":"SI Martin","year":"2011","unstructured":"Martin SI, Dodson B, Wheeler C, Davis J, Pesavento T, Bumgardner GL (2011) Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients. Am J Transplant 11:1058\u20131063. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03478.x","journal-title":"Am J Transplant"},{"key":"6522_CR21","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/ajt.16423","volume":"21","author":"LN Walti","year":"2021","unstructured":"Walti LN, Mugglin C, Sidler D et al (2021) Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study. Am J Transplant 21:2532\u20132542. https:\/\/doi.org\/10.1111\/ajt.16423","journal-title":"Am J Transplant"},{"key":"6522_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14743","volume":"28","author":"IF Ashoor","year":"2024","unstructured":"Ashoor IF, Al-Akash S, Kizilbash S et al (2024) Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: a case series from the pediatric nephrology research consortium. Pediatr Transplant 28:e14743. https:\/\/doi.org\/10.1111\/petr.14743","journal-title":"Pediatr Transplant"},{"key":"6522_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1128\/JCM.38.2.712-715.2000","volume":"38","author":"HGM Niesters","year":"2000","unstructured":"Niesters HGM, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus ADME (2000) Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 38:712\u2013715","journal-title":"J Clin Microbiol"},{"key":"6522_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000557","volume":"2","author":"ML Nijland","year":"2015","unstructured":"Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, ten Berge IJM (2015) Epstein-Barr virus\u2013positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct 2:e48. https:\/\/doi.org\/10.1097\/TXD.0000000000000557","journal-title":"Transplant Direct"},{"key":"6522_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14471","volume":"28","author":"J Preiksaitis","year":"2024","unstructured":"Preiksaitis J, Allen U, Bollard CM et al (2024) The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: III \u2013 consensus guidelines for Epstein-Barr virus load and other biomarker monitoring. Pediatr Transplant 28:e14471. https:\/\/doi.org\/10.1111\/petr.14471","journal-title":"Pediatr Transplant"},{"key":"6522_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/tid.12485","volume":"18","author":"A Chiereghin","year":"2016","unstructured":"Chiereghin A, Prete A, Belotti T et al (2016) Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment. Transpl Infect Dis 18:44\u201354. https:\/\/doi.org\/10.1111\/tid.12485","journal-title":"Transpl Infect Dis"},{"key":"6522_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","volume":"55","author":"R Al Hamed","year":"2020","unstructured":"Al Hamed R, Bazarbachi AH, Mohty M (2020) Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transpl 55:25\u201339. https:\/\/doi.org\/10.1038\/s41409-019-0548-7","journal-title":"Bone Marrow Transpl"},{"key":"6522_CR28","unstructured":"Adapted treatment of Epstein\u2013Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation - ScienceDirect. Accessed July 28, 2024. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1600613522254124?via%3Dihub"},{"key":"6522_CR29","doi-asserted-by":"publisher","unstructured":"Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice (2019) Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33:e13652. https:\/\/doi.org\/10.1111\/ctr.13652","DOI":"10.1111\/ctr.13652"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06522-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:21:38Z","timestamp":1737350498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06522-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6522"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06522-2","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical board approval was given by Rambam Health Care Campus Helsinki committee number 0254\u201324.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent was not requested in this retrospective trial, in line with the approval granted by the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}